相关实验视频
Updated: Jul 17, 2025
05:51
A Human Ex Vivo Atherosclerotic Plaque Model to Study Lesion Biology
Published on: May 6, 2014
13.2K
ADAMTS-7通过降解TIMP-1来调节动脉硬性斑块的形成
M Amin Sharifi1,2, Michael Wierer3, Tan An Dang1,2
1Department of Cardiology, German Heart Centre Munich, Technical University of Munich, Germany (M.A.S., T.A.D., A.M., M.v.S., J.H., P.M., J.W., B.S., H.B.S., H.S., T.K.).
Circulation research
|September 7, 2023
概括
一种分解蛋白和金属蛋白酶-7 (ADAMTS-7) 通过降低金属蛋白酶-1 (TIMP-1) 组织抑制剂的稳定性来促进动脉样硬化,从而增强矩阵金属蛋白酶-9 (MMP-9) 活性和原降解. 抑制ADAMTS-7可能会稳定斑块.
科学领域:
- 心血管生物学 心血管生物学
- 分子医学是分子医学.
- 生物化学 生物化学
背景情况:
- ADAMTS7基因与冠状动脉疾病风险有关.
- ADAMTS-7 (A分解蛋白和金属蛋白酶-7) 是一个细胞外矩阵蛋白酶.
- 降低ADAMTS-7水平可以减少动脉样硬化斑块的形成.
研究的目的:
- 阐明ADAMTS-7有助于动脉样硬化的分子机制.
- 为了确定ADAMTS-7的下游目标,参与疾病发病.
主要方法:
- 蛋白质组学和质谱学被用来识别小鼠动脉样硬化斑块中的ADAMTS-7标.
- 免疫光,体外降解试验和共免疫沉验证了目标相互作用.
- 在人类动脉斑块中分析了ADAMTS7的表达.
主要成果:
- 在不稳定的人类动脉样硬化斑块中,ADAMTS7的表达升高.
- 在小鼠中缺乏ADAMTS-7增加了TIMP-1 (金属蛋白酶-1的组织抑制剂) 水平.
- ADAMTS-7直接结合并降解TIMP-1,减少其对MMP-9 (矩阵金属蛋白酶-9) 的抑制.
- 缺乏ADAMTS-7的小鼠表现出斑块中的原蛋白含量增加,表明MMP-9活性降低.
结论:
- 通过破坏TIMP-1的稳定性,ADAMTS-7促进动脉样硬化,从而增加MMP-9活性和原降解.
- 针对ADAMTS-7和TIMP-1相互作用可能是一个治疗策略,以增强斑块稳定性和减少心血管事件.
更多相关视频
相关概念视频
01:30Atherosclerosis I: Introduction
9
Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
9
01:26Atherosclerosis III: Management
12
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
12
01:26Coronary Artery Disease II: Pathophysiology
12
Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
12
01:23Role of Matrix Metalloproteases in Degradation of ECM
2.4K
Matrix metalloproteases (MMPs) are enzymes involved in the hydrolysis of proteins and glycoproteins of the extracellular matrix. MMPs are essential for the migration and proliferation of cells through the dense matrix network, throughout embryonic development, and throughout morphogenesis. The first MMP activity discovered was a collagenase in a tadpole's tail undergoing metamorphosis. The active collagen deposition and modifications lead to the morphogenesis of tadpoles into the adult...
2.4K
01:38Inflammation
53.8K
Overview
53.8K
01:16Clot Retraction and Fibrinolysis
6.4K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
6.4K